Company intelligence / Profile preview
Pilatus Biosciences
Epalinges, Vaud, Switzerlandpilatusbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Pilatus Biosciences is a preclinical-stage biotech company pioneering immunometabolic therapies. Its lead asset, PLT012—a humanized anti-CD36 antibody—has demonstrated strong preclinical efficacy in liver and colorectal cancers. The molecule received FDA Orphan Drug Designation in late 2024 for liver and intrahepatic bile duct cancers. The company plans to submit its first US IND application and begin clinical trials in 2025.
- Therapeutic areas
- Oncology
- Modalities
- First-in-class antibodiesBifunctional proteins (biologics)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Ludwig Institute for Cancer ResearchUniversity of LausanneCancer Research Institute (New York)
Beyond the preview
Go deeper on Pilatus Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pilatus Biosciences.